astegolimab

01/01/2023 - "Astegolimab or Efmarodocokin Alfa in Patients With Severe COVID-19 Pneumonia: A Randomized, Phase 2 Trial."
01/01/2023 - "Treatment with astegolimab or efmarodocokin alfa did not improve time to recovery in patients with severe COVID-19 pneumonia."
01/01/2023 - "This study aimed to evaluate safety and efficacy of astegolimab, a human immunoglobulin G2 monoclonal antibody that selectively inhibits the IL-33 receptor, ST2, or efmarodocokin alfa, a human IL-22 fusion protein that activates IL-22 signaling, for treatment of severe COVID-19 pneumonia. "

01/01/2023 - "Astegolimab or Efmarodocokin Alfa in Patients With Severe COVID-19 Pneumonia: A Randomized, Phase 2 Trial."
01/01/2023 - "Treatment with astegolimab or efmarodocokin alfa did not improve time to recovery in patients with severe COVID-19 pneumonia."
01/01/2023 - "This study aimed to evaluate safety and efficacy of astegolimab, a human immunoglobulin G2 monoclonal antibody that selectively inhibits the IL-33 receptor, ST2, or efmarodocokin alfa, a human IL-22 fusion protein that activates IL-22 signaling, for treatment of severe COVID-19 pneumonia. "

10/01/2021 - "A repeated time-to-event (RTTE) model for exacerbations was developed using data from a 52-week phase IIb trial, including 502 patients with asthma randomized to placebo or 70 mg, 210 mg, or 490 mg astegolimab every 4 weeks. "
01/01/2021 - "This study evaluated astegolimab efficacy and safety in patients with severe asthma. "
01/01/2022 - "Population Pharmacokinetics and Exposure-Response Relationships of Astegolimab in Patients With Severe Asthma."
01/01/2021 - "Astegolimab reduced AER in a broad population of patients, including those who were eosinophil-low, with inadequately controlled, severe asthma. "
01/01/2021 - "Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trial."

01/01/2022 - "Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease (COPD-ST2OP): a phase 2a, placebo-controlled trial."
01/01/2022 - "In patients with moderate-to-very severe COPD, astegolimab did not significantly reduce exacerbation rate, but did improve health status compared with placebo. "
01/01/2022 - "We aimed to determine whether astegolimab, a selective ST2 IgG2 monoclonal antibody, reduces exacerbations in COPD. "

12/01/2022 - "This was a randomized, placebo-controlled, phase 2 study in which adults with chronic atopic dermatitis were randomized 1:1 to receive astegolimab 490 mg every 4 weeks or placebo, for 16 weeks. "
12/01/2022 - "This study sought to assess the efficacy, safety, and pharmacokinetics of astegolimab in patients with atopic dermatitis. "
12/01/2022 - "In patients with atopic dermatitis, astegolimab did not show a significant difference compared to placebo for the primary or secondary outcomes."
12/01/2022 - "Phase 2 randomized clinical trial of astegolimab in patients with moderate to severe atopic dermatitis."